At close: December 20 at 5:29:35 PM GMT+1
Breakdown
TTM
8/31/2024
8/31/2023
8/31/2022
8/31/2021
Total Revenue
130.00
130.00
546.00
454.00
253.00
Cost of Revenue
3,710.00
3,710.00
3,634.00
4,403.00
2,501.00
Gross Profit
-3,580.00
-3,580.00
-3,088.00
-3,949.00
-2,248.00
Operating Expense
143,694.00
143,694.00
112,758.00
110,987.00
83,633.00
Operating Income
-147,274.00
-147,274.00
-115,846.00
-114,936.00
-85,881.00
Net Non Operating Interest Income Expense
3,745.00
3,745.00
1,048.00
8,006.00
1,512.00
Pretax Income
-151,850.00
-151,850.00
-116,073.00
-103,516.00
60,045.00
Net Income Common Stockholders
-151,850.00
-151,850.00
-116,073.00
-103,517.00
60,046.00
Diluted NI Available to Com Stockholders
-151,850.00
-151,850.00
-116,073.00
-103,517.00
60,046.00
Basic EPS
-1.60
--
-1.50
-1.37
0.88
Diluted EPS
-1.60
--
-1.50
-1.37
0.88
Basic Average Shares
94,712.58
--
78,285.57
78,384.57
71,485.18
Diluted Average Shares
94,712.58
--
78,285.57
78,384.57
71,485.18
Total Operating Income as Reported
-146,567.00
-146,567.00
-120,806.00
-118,176.00
-85,880.00
Total Expenses
147,404.00
147,404.00
116,392.00
115,390.00
86,134.00
Net Income from Continuing & Discontinued Operation
-151,850.00
-151,850.00
-116,073.00
-103,517.00
60,046.00
Normalized Income
-137,295.00
-137,295.00
-116,073.00
-110,170.00
-84,368.00
Interest Income
3,753.00
3,753.00
1,051.00
8,259.00
1,965.00
Interest Expense
8.00
8.00
3.00
253.00
453.00
Net Interest Income
3,745.00
3,745.00
1,048.00
8,006.00
1,512.00
EBIT
-151,842.00
-151,842.00
-116,070.00
-103,263.00
60,498.00
EBITDA
-140,851.00
-140,851.00
-111,201.00
-98,880.00
61,280.00
Reconciled Cost of Revenue
3,710.00
3,710.00
3,634.00
4,403.00
2,501.00
Reconciled Depreciation
10,991.00
10,991.00
4,869.00
4,383.00
782.00
Net Income from Continuing Operation Net Minority Interest
-151,850.00
-151,850.00
-116,073.00
-103,517.00
60,046.00
Total Unusual Items Excluding Goodwill
-14,555.00
-14,555.00
--
6,653.00
144,414.00
Total Unusual Items
-14,555.00
-14,555.00
--
6,653.00
144,414.00
Normalized EBITDA
-126,296.00
-126,296.00
-111,201.00
-105,533.00
-83,134.00
8/31/2021 - 5/20/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NXTCL.ST NextCell Pharma AB
2.6600
+3.10%
ISOFOL.ST Isofol Medical AB (publ)
2.4050
-3.80%
CANTA.ST Cantargia AB (publ)
1.8490
+0.76%
XINT.ST Xintela AB (publ)
0.3260
+1.88%
FLERIE.ST Flerie AB (publ)
48.34
+0.71%
MVIR.ST Medivir AB (publ)
2.7600
-1.08%
65G.F NextCell Pharma AB
0.1855
+9.12%
LPGO.ST Lipigon Pharmaceuticals AB (publ)
0.1378
-13.77%
NANECH.ST NanoEcho AB
0.1580
+21.54%
COMBI.ST CombiGene AB (publ)
2.7200
+5.43%